Karin H. Cerri

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Impact of Stigma on People Living with Chronic Hepatitis B.

Impact of Stigma on People Living with Chronic Hepatitis B.

Journal: Patient related outcome measures

Published: August 12, 2019

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.

Journal: Journal of medical economics

Published: March 13, 2015

Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.

Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.

Journal: PharmacoEconomics

Published: January 12, 2015

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy.

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Journal: BMC infectious diseases

Published: August 19, 2014

Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis.

Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 04, 2014

Validation of the Fatigue Severity Scale in chronic hepatitis C.

Validation of the Fatigue Severity Scale in chronic hepatitis C.

Journal: Health and quality of life outcomes

Published: September 19, 2013

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.

Journal: BMC infectious diseases

Published: September 12, 2013

Decision making by NICE: examining the influences of evidence, process and context.

Decision making by NICE: examining the influences of evidence, process and context.

Journal: Health economics, policy, and law

Published: May 22, 2013

Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.

Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: July 04, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026